Successful Tepotinib Rechallenge after Tepotinib-induced Adverse Events Following Pembrolizumab Failure in a Case of Non-small Cell Lung Carcinoma with MET Exon 14 Skipping.

Yuichiro Yasuda, Yoshihiro Hattori, Miyako Satouchi

Abstract readCase Reports

In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Challenges and Limitations of Sequential MET-TKI Therapy in METex14- Positive NSCLC With a Focus on Non-ILD Toxicities: A Case Report.Cancer reports (Hoboken, N.J.) · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuichiro YasudaDepartment of Thoracic Oncology, Hyogo Cancer Center, Japan.

Yoshihiro HattoriDepartment of Thoracic Oncology, Hyogo Cancer Center, Japan.

Miyako SatouchiDepartment of Thoracic Oncology, Hyogo Cancer Center, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a case of successful rechallenge with tepotinib after tepotinib-induced adverse events following first-line treatment failure with pembrolizumab in a patient with non-small cell lung carcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutations. Initial tepotinib administration was suspended because of hepatotoxicity and hypersensitivity. However, the re-administration of tepotinib after a prolonged interval from pembrolizumab administration achieved sustained disease control. The patient continued tepotinib treatment for approximately two years after the first administration. Therefore, the treatment sequence should be considered based on comprehensive multigene testing results to achieve better therapeutic benefits.

Indexed as

Antibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungLung NeoplasmsPiperidinesProto-Oncogene Proteins c-metPyridazinesPyrimidinesAgedAntineoplastic Agents, ImmunologicalExonsFemaleHumansMaleMiddle AgedMutationTreatment FailureAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalMET protein, humanpembrolizumabPiperidinesProto-Oncogene Proteins c-metPyridazinesPyrimidinestepotinibimmune checkpoint inhibitorimmune-related adverse eventMET exon 14 skipping mutationsnon-small cell lung carcinomatepotinib

Identifiers

PMID40993084

DOI10.2169/internalmedicine.6084-25

PMCPMC13222686

What Socratic holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.